Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
05 Noviembre 2024 - 6:00AM
Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a
biopharmaceutical company focused on developing modality-agnostic
targeted therapies, today announced that Nadim Ahmed, Chief
Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical
Officer, will participate in a fireside chat at the Stifel 2024
Healthcare Conference, being held in New York on November 18 and
19, 2024.
The fireside chat is scheduled for Tuesday, November 19, 2024,
at 1:50 p.m. ET. A webcast of the fireside chat will be available
under the Events and Presentations section of the Company’s
investor relations website at
https://cullinantherapeutics.com/events-and-presentations/.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a
biopharmaceutical company dedicated to creating new standards of
care for patients. Cullinan has strategically built a diversified
portfolio of clinical-stage assets that inhibit key drivers of
disease or harness the immune system to eliminate diseased cells in
both autoimmune diseases and cancer. Cullinan’s portfolio
encompasses a wide range of modalities, each with the potential to
be best and/or first in class. Anchored in a deep understanding of
oncology, immunology, and translational medicine, we create
differentiated ideas, identify the most appropriate targets, and
select the optimal modality to develop transformative therapeutics
across a wide variety of autoimmune and cancer indications. We push
conventional boundaries from candidate selection to differentiated
therapeutic, applying rigorous go/no go criteria at each stage of
development to fast-track only the most promising molecules to the
clinic and, ultimately, commercialization. With deep scientific
expertise, our teams exercise creativity and urgency to deliver on
our promise to bring new therapeutic solutions to patients. Learn
more about Cullinan at https://cullinantherapeutics.com/, and
follow us on LinkedIn and X.
Contacts:
Investor RelationsNick Smith+1
401.241.3516nsmith@cullinantx.com
MediaRose Weldon+1
215.801.7644rweldon@cullinantx.com
Cullinan Therapeutics (NASDAQ:CGEM)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Cullinan Therapeutics (NASDAQ:CGEM)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024